GlassScriptPhysician profile
Douglass Green
NPI 1871590166
$1,659.37
in general payments reported to CMS, 2019-2025
28 companies · $99.14 in 2025
The $99.14 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $168 · 2021: $385 · 2022: $313 · 2023: $137 · 2024: $400 · 2025: $99.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $242.10 | 2021-2024 | |
| Novo Nordisk INC | $229.24 | 2019-2024 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $141.28 | 2022-2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $137.04 | 2019-2025 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $130.57 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $99.07 | 2022-2024 | Tarpeyo |
| Glaxosmithkline, LLC. | $70.51 | 2021 | |
| Amgen INC. | $57.83 | 2024-2025 | Tavneos, Evenity |
| Lundbeck LLC | $50.95 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $50.30 | 2019-2022 | |
| Biogen, INC. | $46.33 | 2021 | |
| Pfizer INC. | $42.48 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $41.38 | 2024 | Acthar |
| Inogen, INC. | $37.06 | 2022-2025 | |
| Horizon Therapeutics Plc | $34.75 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $32.60 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.03 | 2020 | |
| Eisai INC. | $23.79 | 2024 | |
| Lilly USA, LLC | $23.00 | 2024 | Jardiance, Zepbound |
| Travere Therapeutics, INC. | $19.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.23 | 2024 | Eliquis |
| Amarin Pharma, INC. | $15.91 | 2021 | |
| Opko Pharmaceuticals, LLC | $15.84 | 2022 | |
| Corium, LLC | $15.40 | 2023 | Adlarity |
| Antares Pharma, INC. | $14.57 | 2024 | Xyosted |
| Paratek Pharmaceuticals, INC. | $13.34 | 2024 | Nuzyra |
| Almatica Pharma LLC | $12.75 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglass Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.